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Background: L-BLP25 antigen-specific cancer immunotherapeutic agent is currently in phase III clinical trials for
non-small cell lung cancer. Using a novel human MUC1 transgenic (hMUC1.Tg) lung cancer mouse model, we
evaluated effects of L-BLP25 combined with low-dose cyclophosphamide (CPA) pretreatment on Th1/Th2 cytokine
production and antitumor activity.
Methods: A chemically-induced lung tumor model was developed in hMUC1.Tg C57BL/6 mice by administering
10 weekly 0.75-mg/g doses of the chemical carcinogen urethane by intraperitoneal injection. Serum cytokines
associated with Th1/Th2 polarization and inflammation were measured by multiplex cytokine assay during
tumorigenesis. Antitumor activity of L-BLP25 (10 μg) with CPA (100 mg/kg) pretreatment was evaluated following
either one or two eight-week cycles of treatment by preparing lung whole mounts and counting tumor foci, and
assessing IFN-γ production by ELISpot assay.
Results: During the carcinogenesis phase, no detectable Th1- or Th2-associated cytokine responses were observed,
but levels of pro-inflammatory cytokines were increased with distinctive kinetics. A single cycle of L-BLP25
consisting of eight weekly doses was ineffective, whereas adding a second cycle given during tumor progression
showed a significant reduction in the incidence of tumor foci. Administering two cycles of L-BLP25 induced Th1
cytokines IL-12, IL-2 and IFNγ at 24 h after the last dose, while Th2 and inflammatory cytokines were elevated to a
lesser extent.
Conclusions: Urethane-induced lung tumors in hMUC1.Tg mice can be used as a model to assess the efficacy of
the MUC1 antigen-specific cancer immunotherapeutic agent L-BLP25. The results indicate that the antitumor
response to L-BLP25 requires at least two cycles and pre-treatment with CPA. In addition, monitoring pro-
inflammatory serum cytokines may be useful as a biomarker of L-BLP25 response. Taken together, the preclinical
lung tumor model can be utilized for determining effective combinations of L-BLP25 with chemotherapy and/or
other immunotherapies.
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Lung cancer is the leading cause of cancer death in men
and women, with an overall 5-year survival rate of ap-
proximately 10 to 15% [1]. The limited efficacy and the
toxicity associated with chemotherapy for non-small cell
lung cancer (NSCLC) has created a need for safer and
more efficacious treatment options. With the identifica-
tion of tumor-associated antibodies and antigens (TAA) in
patients with lung cancer, immunotherapy has emerged as
an attractive alternative [2,3].
Mucin 1 (MUC1) is one such TAA that is an epithelial
glycoprotein overexpressed in NSCLC. T-cells specific
for antigenic epitopes of MUC1 that bind to HLA class
I molecules have been identified and isolated from the
blood and bone marrow of cancer patients [4,5]. The
immunodominant peptides from the variable number of
tandem repeat region (VNTR) are recognized by the
cytotoxic T-lymphocytes (CTL), making MUC1 an at-
tractive target for therapeutic intervention [6]. A num-
ber of studies have shown that MUC1 may facilitate
epithelial carcinogenesis [7-12]. High MUC1 expression
in tumors has been correlated with increased invasive-
ness, migration, and angiogenesis in ovarian and lung
cancers [7,9]. Depolarized expression of MUC1 has
been related to poor prognosis in early stage NSCLC
[8,10,11]. Recent findings have indicated that NSCLC cells
are dependent on the MUC1-C terminal cytoplasmic
domain for both activation of the phosphatidylinositol
3-kinase (PI3K)-Akt pathway and for survival [12].
A number of studies are focused on devising techniques
to effectively present MUC1 as an immunogen to stimu-
late a strong and highly specific immune response against
target cells overexpressing MUC1. L-BLP25 is one such
innovative liposomal antigen-specific cancer immunother-
apy currently under development that contains 25 amino
acids from the immunogenic tandem-repeat region of
MUC1 [13]. L-BLP25 is an active immunotherapeutic
agent designed to induce a cellular immune response by
targeting T-cell epitopes from the VNTR region of the
MUC1 antigen associated with HLA class I molecules
[14]. Although NSCLC is historically regarded as a non-
immunogenic cancer [15], L-BLP25 in phase II clinical tri-
als has shown survival advantages with a remarkably low
toxicity profile [16,17]. In these trials a single, low, intra-
venous dose (300 mg/m2 to a maximum of 600 mg) of
cyclophosphamide (CPA) is administered three days prior
to immunotherapy. This procedure is thought to enhance
delayed-type hypersensitivity humoral and cellular im-
mune responses by reducing T-suppressor function. Al-
though CPA lacks any significant activity in NSCLC [18],
and the dose used in this setting is below that used in
cytotoxic chemotherapy, it is unknown whether any of the
observed antitumor effects following L-BLP25 therapy can
be attributed to the immunomodulatory effects of CPA.Recent gene profiling studies comparing signaling path-
ways in cancer among different species have detected
marked similarities in mouse and human lung tumorigen-
esis [19,20]. Various approaches have been adopted to cre-
ate a lung cancer mouse model, in which lung tumors
may develop spontaneously or be induced with chemical
carcinogens, transgenic oncogenes, viruses or radiation
[21]. Unfortunately, there has been no well-established
mouse model to study hMUC1-positive lung cancer.
Rowse et al. produced a transgenic mouse model that ex-
presses hMUC1 on an inbred C57BL/6 background [22].
However, C57BL/6 and DBA background mice are ex-
tremely resistant to lung carcinogenesis [23]. In spite of
this limitation, previous studies in C57BL/6 mice have
shown that 10 weekly injections of urethane at 1 mg/g
caused a high incidence of lung adenomas [24]. In ad-
dition, Jiang et al. showed that diethylstilbestrol (DES) can
promote the effects of urethane-induced mouse lung
tumorigenesis in female Kunming mice [25].
The primary objectives of the current study were: (1) to
develop a hMUC1-expressing lung tumor mouse model
and utilize it to: (2) evaluate the effects of low-dose CPA
on the L-BLP25-induced serum cytokine response; and (3)
compare the antitumor activity of L-BLP25 with CPA pre-
treatment following one and two cycles of treatment.
Methods
Chemicals
Urethane and cyclophosphamide were purchased from
Sigma-AldrichW (St. Louis, MO). Diethylstilbestrol was
purchased from Medisca (Plattsburgh, NY). L-BLP25
vaccine and the peptides used in ELISpot (BP25 and
BP1-424) were provided by Merck Serono Research,
Merck KGaA, Darmstadt, Germany.
Animals
A total of 179 MUC1.Tg and 10 wild type C57BL/6 mice
were supplied by our breeding colony maintained by the
UC Davis Mouse Biology Program and housed at the UC
Davis Center for Laboratory Animal Science vivarium. To
establish the colony, heterozygous hMUC1 female trans-
genic founder mice were purchased from Mayo Clinic
(Scottsdale, AZ). The mice were kept in cages (4 mice/
cage) maintained at constant temperature and humidity
with a 12-h light/12-h dark cycle. All mice received free
access to water and Purina Laboratory Rodent Diet
(LabDietW 5001, PMIW Nutrition International, St. Louis,
MO). All animal studies were conducted under a protocol
approved by the University of California Davis Institu-
tional Animal Care and Use Administrative Advisory
Committee. UC Davis is an Association for Assessment
and Accreditation of Laboratory Animal Care accredited
institution. For all mouse studies, the week number refers
to the age of the mice in each respective study.
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For DNA extraction, toe clippings from two-week old
mice were placed in a 96-well plate. Next, 40 μl of 50 mM
NaOH was added to each well, and plates were heated to
94°C for 10 min. Extracted DNA was neutralized with
20 μl of 1 M Tris (pH 8) per well. Plates were sealed,
vortexed briefly, centrifuged (6000 rpm × 2 min), and
stored at −20°C until use. Polymerase chain reaction was
used to identify MUC1.Tg mice using an ABI Prism
7900HT Sequence Detection System (AB Applied
Biosystems, Carlsbad, CA). MTag forward and reverse
primers were 5′-TTGGAGAATGTTTTTGTCTTGAA
TG and 3′-CAGCACATCTCGGGTTGGT. The MTag
TaqMan probe (ACATGCAATGGTTTGGAA) carrying a
6′ FAM reporter label and a 3′ MGBNFQ quencher group
was used. For MUC1, forward and reverse primers were
5′-CACTCTTCCCCCAACCTTAAGTG and 3′-GGGTG
GGTGGTGGTCATG. The MUC1 TaqMan probe (ACC
AGTCCCTCCCTACG) carrying a 5′ VIC reporter label
and a 3′ MGBNFQ was used. The amplification program
consisted of one cycle of 2 min at 95°C and 40 cycles of
15 sec each at 60°C and 95°C.
Immunohistochemistry (IHC)
The lungs, left kidney and spleen were harvested from
each mouse at the time of sacrifice, which was performed
by CO2 asphyxiation. The lungs were filled with 10% neu-
tral buffered formalin prior to excision. All tissue samples
were fixed in 10% buffered formalin overnight, followed
by 70% ethanol until processed. Tissues were then paraffin
embedded and step-sectioned at 4 μm for immunohisto-
chemical analysis. Immunohistochemistry was performed
using a MUC1 antibody (CD227, 550486; 1:400; BD
Pharmingen) which recognizes the tandem-repeat re-
gion. The Animal Research Kit peroxidase (ARK;
K3954; Dako) was used to minimize reactivity of sec-
ondary mouse antibody with endogenous immuno-
globulin present in the tissue. Lung whole mounts
were prepared using standard protocols.
Multiplex cytokine assays
The Mouse Cytokine 20-plex Panel (Invitrogen; cat.
#LMC0006, Carlsbad, CA) was used to analyze the levels
(pg/mL) of Th1/Th2 and inflammatory cytokines in all
serum samples except for those from the studies de-
scribed under “Different Schedules of L-BLP25”, for which
a 25-plex Milliplex MAP Mouse Cytokine/Chemokine
Magnetic Bead Panel (Millipore, Billerica, MA) was used.
The 20-plex panel consisted of interleukin (IL) -1α, IL-1β,
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, interferon
gamma (IFN-γ), interferon gamma-induced protein 10
(IP-10), monokine induced by IFN-γ (MIG), keratinocyte
derived cytokine (KC), monocyte chemotactant protein-1
(MCP-1), macrophage inflammatory protein-1 alpha(MIP-1α), granulocyte/macrophage colony stimulating fac-
tor (GM-CSF), vascular endothelial growth factor (VEGF),
tumor necrosis factor alpha (TNF-α), and basic fibroblast
growth factor (FGF-basic). In addition to the analytes listed
for the 20-plex panel, with the exception of VEGF, MIG,
and FGF-basic, the 25-plex panel included granulocyte
colony-stimulating factor (G-CSF), IL-7, IL-9, IL-12 (p40/
p70), IL-15, MIP-1β, MIP-2, and regulated on activation,
normal T-cell expressed and secreted (RANTES). The as-
says were performed according to their respective manu-
facturer’s instructions. The concentration of each cytokine
was calculated relative to respective standard curves. For
20-plex analyses, cytokine concentrations were acquired
on a BioPlex System using BioPlex software version 5.0
(BioRad, Hercules, CA, USA). The 25-plex analysis was
performed on a Luminex 100/200 system running xPonent
software version 3.1 (Luminex Corporation, Austin, TX).
In-house control
To establish the in-house control for this assay, wildtype
C57BL/6 mice were challenged with lipopolysaccharide
(LPS). Mice were injected intraperitoneally (i.p.) with
200 μg LPS from Escherichia coli serotype O111:B4
(Sigma-Aldrich) dissolved in 1X PBS. At 4–5 h post-
injection, mice were euthanized by CO2 asphyxiation.
Whole blood was collected by cardiac puncture and
placed in a clotting tube for isolation of serum by centri-
fugation. The serum was flash frozen in liquid nitrogen
and stored at −80°C until analysis by multiplex assays on
Luminex system.
Lung cancer model development in MUC1.Tg mice
For this study, 38 male MUC1.Tg mice (5 weeks of age)
were divided into five groups: Control (vehicle only) (n = 8);
Urethane (n = 10); Urethane +DES 7 mg/kg (n = 10); and
Urethane +DES 14 mg/kg (n = 10). A second urethane
group composed of 10 wild type males was included to
compare human MUC1 expression with the transgenic
mice. Urethane (0.75 mg/g) or sterile water (control) was
administered by i.p. injection weekly for 10 weeks using
a 25-gauge needle. All injection volumes were 100 μl.
Starting 24 h after urethane dose 4, DES (7 mg/kg or
14 mg/kg) or corn oil (control) was administered weekly
for a total of 8 weeks by subcutaneous (s.c.) injection in a
volume of 100 μl using a 25-gauge needle. Mice were
monitored until termination of the study in Week 38. The
lungs, spleens, and left kidneys were collected and ana-
lyzed from a total of 46 mice. The presence of hMUC1-
expressing lung adenoma was confirmed by blinded IHC
evaluations performed by a pathologist.
Cytokine response in MUC1.Tg mice
We studied the polarization of cytokine response in the
hMUC1.Tg model during the induction and progression
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hMUC1.Tg mice were bled 24 h after the 5th, 8th, and
10th doses of urethane (Weeks 10, 12, and 15, respect-
ively) and thereafter at approximately four-week in-
tervals (Weeks 20–40). Urethane administration was
performed starting at approximately 4 weeks of age, as de-
scribed under Lung Cancer Model Development in
MUC1.Tg mice. Whole blood was collected from mice via
submandibular bleeds, pooled and allowed to clot for
30 min, and then serum was isolated by centrifugation for
10 min at 3500 × g. Serum was flash frozen in liquid nitro-
gen and stored at −80°C until analysis by Luminex assay.
Effect of single dose of Cyclophosphamide on Th1/Th2
cytokine response
To determine the effect of low-dose CPA on the L-BLP25-
induced immune response, and whether low-dose CPA
induces a Th2/Th1 cytokine shift in this model, a total of
103 MUC1.Tg mixed sex C57BL/6 mice were divided into
five treatment groups: Control (n = 20), CPA 100 mg/kg
(n = 21), CPA 300 mg/kg (n = 20), L-BLP25 alone (n = 21)
and CPA 100 mg/kg + L-BLP25 (n = 21). Each group
contained 13 male and 8 female mice, except for the con-
trol and CPA 300 mg/kg groups, which each contained
seven females. All mice underwent 10 weeks of urethane
dosing at 0.75 mg/g weekly starting at 4 weeks of age. At
Week 14, four days after urethane dosing was completed,
mice were administered a single dose of CPA at either 100
or 300 mg/kg by i.p. injection according to treatment
group assignment. Whole blood was collected from mice
in each treatment group via submandibular bleeds 24 h
following CPA administration. In our L-BLP25 mouse
studies we have been using a CPA dose of 100 mg/kg,
which is equivalent to the 300-mg/m2 dose used in
humans [26]. Three days after CPA administration, mice
were given s.c. injections of 10 μg L-BLP25 at rotating
sites according to treatment group using a 25-gauge nee-
dle once each week for eight weeks, with the 8th dose be-
ing administered in Week 21. The lyophilized L-BLP25
was reconstituted in sterile 0.9% saline to a concentration
of 100 μg/ml and delivered in a volume of 100 μl. Twenty-
four hours after the 4th and 8th doses of L-BLP25, whole
blood was collected from mice in each treatment group
via submandibular bleeds. Blood was pooled within a
treatment group and serum was isolated by centrifugation.
The serum was flash frozen in liquid nitrogen and stored
at −80°C until analysis by Luminex assay. In order to assess
the antitumor effects of CPA when combined with L-
BLP25, this study was continued through Week 41 as de-
scribed below in the two-cycle dosing study.
Different schedules of L-BLP25
Two studies were conducted in order to determine the ef-
fects of L-BLP25 on the development of lung tumors inthis mouse model following either one or two cycles of
treatment. In the first study, 32 MUC1.Tg male C57BL/6
mice were divided into four treatment groups: Untreated;
CPA 100 mg/kg; L-BLP25 alone; and L-BLP25 + CPA
100 mg/kg (n = 8, all groups). All mice received 10 weekly
i.p. injections of 0.75 mg/g urethane starting at four weeks
of age as described under model development. Cyclophos-
phamide was then prepared and administered as described
above, 24 h following the final urethane dose (Week 13).
A single eight-dose cycle of weekly L-BLP25 was begun
three days following CPA administration (Week 14).
L-BLP25 was prepared as described above and admin-
istered weekly for a total of eight 10-μg doses by s.c.
injection at rotating sites using a 25-gauge needle (in-
jection volume 100 μl). Mice were then followed for 20
additional weeks. At the conclusion of the study in Week
41, all mice were euthanized by CO2 asphyxiation. Whole
blood was then collected by cardiac puncture, and lung
whole mounts were prepared to compare average lung
tumor numbers between groups. Serum was isolated from
whole blood and stored as described above.
In the two-cycle L-BLP25 study, which was a continu-
ation of the low-dose CPA study described above, a total
of 65 male and female MUC1.Tg C57BL/6 mice in four
treatment groups were utilized. To reiterate, the treat-
ment groups were Untreated (n = 18), CPA 100 mg/kg
(n = 17), L-BLP25 alone (n = 14), and L-BLP25 + CPA
100 mg/kg (n = 16). The CPA 300 mg/kg group was ex-
cluded. This study was designed as described for the
single-cycle study, except that 11 weeks following the
end of the first eight-dose cycle of L-BLP25 (Week 32),
these mice began a second cycle of treatment that con-
tinued weekly until the conclusion of the study in Week
41. The second cycle consisted of a total of nine 10-μg
doses of L-BLP25, which was prepared and administered
as described above. Three days prior to beginning the
second cycle of L-BLP25, another 100-mg/kg dose of
CPA was administered. At the end of the study, mice
were euthanized by CO2 asphyxiation, and whole blood
was collected by cardiac puncture. Serum was isolated
and stored as described above for Luminex system ana-
lysis. Following blood collection, lung whole mounts
were prepared to compare total average tumor numbers
between treatment groups. IFN-γ/IL-4 ELISpot analysis
was performed as detailed below on four mice from each
treatment group to assess immune response.
ELISpot
To assess the immune response to L-BLP25 following
one and two cycles of treatment, splenocytes from
L-BLP25-treated and untreated mice were examined for
Th1/Th2 polarization by analyzing two key cytokines:
IFN-γ for Th1 and IL-4 for Th2 polarization. Dual color
ELISpot mouse IFN-γ/IL-4 (R&D Systems, Minneapolis,
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aseptically, processed through 100-μm nylon tissue
sieves (Becton Dickinson, Franklin Lakes, NJ) into sterile
PBS, and the cell suspensions were layered over lympho-
cyte separation medium (Lonza, Walkersville, MD). Lym-
phocytes were isolated by centrifuging at 600 × g for
15 min, washed in PBS, and then resuspended in improved
minimum essential medium (Invitrogen) containing 10%
fetal bovine serum (HyClone, Logan, UT), 50 μg/ml
streptomycin and 50 U/ml penicillin (Invitrogen) prior to
counting and viability assessment using an Auto T4
Cellometer™ (Nexcelom Bioscience, Lawrence, MA). BP25
peptide and scrambled peptide (BP1-424) were prepared at
a final concentration of 5 μg/ml in culture medium. Lym-
phocytes (1.0 × 106/well) were incubated with either no
peptide (medium only), BP25, or scrambled peptide in trip-
licate at 37°C overnight. ELISpot plates were developed
according to the manufacturer’s instructions.
Statistical methods
Differences in tumor incidence between experimental
groups in the model development study were evaluated
for statistical significance using Fisher’s exact test (two-
tailed). In the one- and two-cycle L-BLP25 studies, a
one-way ANOVA was used for comparisons between
average number of lung tumors between the various
treatment groups. Bonferroni’s adjustment for multiple
comparisons was used to lessen the likelihood of a false
positive result. GraphPad PrismW 5 software was used
for all statistical analyses. A p-value of ≤ 0.05 was consid-
ered significant for all analyses.
Results
Urethane induces hMUC1-expressing lung adenomas
MUC1.Tg mice treated with urethane alone developed
lung adenomas with a tumor incidence rate of 100%, while
urethane in combination with DES resulted in tumor inci-
dence rates of 50% and 67% at the 7- and 14-mg/kg DES
dose levels, respectively. Lung tumor incidence following
treatment with urethane alone was significantly greater
than urethane combined with 7 mg/kg DES (p = 0.0302),
but not urethane plus 14 mg/kg DES. These results indi-
cate that the addition of DES treatment did not increase
tumor incidence, in contrast to Jiang et al. [25]. Further-
more, it is evident that urethane alone at a dose of
0.75 mg/g injected weekly for 10 weeks was sufficient to
induce lung adenomas in MUC1.Tg C57BL/6 mice.
Histopathological evaluation
As shown in Figure 1, histopathological evaluation of
urethane-treated mouse lungs revealed adenoma with
high expression of hMUC1. Urethane exposure consist-
ently resulted in pulmonary neoplasms of varying size
and with some variation in phenotype ranging frompapillary to trabecular and solid. Neoplastic foci were
seen in both central and peripheral areas of the lung
parenchyma, but consistently arose in alveolar spaces,
and not from larger bronchi. By comparison, these foci
appear most similar to human bronchioloalveolar carcin-
omas, and in the earliest stages (smallest foci) are similar
to human atypical adenomatous foci. Arbitrary size cri-
teria have been used traditionally to divide rodent pul-
monary neoplasms into adenoma or carcinoma, but
more recently, recommendations from the NCI Mouse
Models of Human Cancers Consortium consensus meet-
ing on mouse models of lung cancer has recommended
against using the term “bronchioloalveolar” when refer-
ring to mouse lung lesions in favor of the more simpli-
fied terms of adenoma or adenocarcinoma [27]. All
sections were reviewed blinded to cohort conditions. All
spleens from the MUC1-expressing mice were negative
and all kidneys positive for hMUC1 expression.
Time course of cytokine response during tumor
development
We studied the polarization of cytokine response in
MUC1.Tg mice at different phases of tumor develop-
ment. Mice were bled approximately 24 h after the 5th,
8th and 10th doses of urethane, and thereafter at approxi-
mately 4-week intervals. Cytokines were grouped into
Th1 type (IL-2, IL-12, GMCSF, IFN-γ, TNF-α, IL-17), Th2
(IL-4, IL-5, IL-6, IL-10, IL-13), and inflammatory/chemo-
kine type (IL-1α, IL-1β, IP-10, MIG, KC, MCP-1, MIP-1
α). The Th1 cytokines IL-2, IL-12, IL-17, TNF-α, GMCSF
and IFN-γ, and Th2 cytokines IL-4, IL-5, IL-6, IL-10 and
IL-13 demonstrated no consistent pattern (data not
shown), suggesting that urethane has minimal effects on
Th1/Th2 cytokine polarization. Figure 2 shows the levels of
pro-inflammatory cytokines at different stages of model de-
velopment. Potent inflammatory cytokines IL-1α and MIP-
1α were elevated during Week 10, which may be result of
an inflammatory response to urethane exposure. Levels of
these cytokines and other pro-inflammatory cytokines
such as IP-10, MIG, KC, MCP-1, and MIP-1α were
elevated post Week 20 (see Figure 2), which may
be a result of an inflammatory response associated with
tumor progression.
Single Low-dose Cyclophosphamide potentiates L-BLP25-
induced Th1 cytokine response
In order to evaluate the effect of low-dose CPA on the
L-BLP25-induced Th1 cytokine response, we utilized a
multiplex assay to analyze serum collected 24 h after
the 4th and 8th weekly doses of L-BLP25. Cytokines ana-
lyzed were grouped as follows: Th1 type (IL-2, IL-12,
IFN-γ), Th2 (IL-4, IL-5, IL-6, IL-13), and inflammatory/
chemokine type (IP-10, MIG, KC, MCP-1, MIP-1α).
Using this multiplex assay we found noticeable differences
Figure 1 Comparison of hMUC1 expression in lung tissues and tumors from MUC1.Tg vs. wild type mice at week 38. (A) Lung tissue
from a MUC1.Tg control mouse exhibiting hMUC1 positivity and normal H&E staining. (B) Lung tissue from a urethane-treated wild type mouse
exhibiting hMUC1-negative adenoma; the H & E staining shows a representative tumor region (arrow). (C) Lung tissue from a urethane-treated
MUC1.Tg mouse exhibiting hMUC1-positive adenoma; the H&E staining shows a representative tumor region (arrow). Magnification = 60X
(all panels). A number of samples showed tumors with multiple foci.
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pared to mice given the combination of CPA 100 mg/kg
and L-BLP25.
For Th1 cytokines, the levels of IL-2 and IFN-γ showed
an elevated trend in the CPA + L-BLP25 treated mice in
comparison to L-BLP25 alone 24 h following the 4th and
8th doses (Figure 3A and 3C). For IL-12, the levels were el-
evated in the L-BLP25 alone treatment group compared
to the CPA 100 mg/kg + L-BLP25 group 24 h post-dose 4
(Figure 3A), whereas the post-dose 8 levels were elevated
in the CPA 100 mg/kg + L-BLP25 group compared to the
L-BLP25 alone group (Figure 3C). This discrepancy could
be a result of samples being pooled together within a treat-
ment group. Although the IL-12 levels were inconclusive,
the post-L-BLP25 dose 4 levels of two other main Th1 cy-
tokines (IL-2 & IFN-γ) were elevated in the CPA 100 mg/
kg + L-BLP25 group in comparison to the L-BLP25 alonegroup, and a similar trend was observed following dose 8.
While some of the Th2 cytokines also showed an elevated
trend in the CPA + L-BLP25 treated mice in comparison
to mice treated with L-BLP25 alone following the 4th and
8th dose (Figures 3B and 3D), on balance the predominant
immune response was Th1 polarized, as evidenced by the
noticeably elevated IFN-γ levels.
Levels of inflammatory cytokines (IP-10, MIG, KC,
MCP-1, MIP-1α) trended towards being elevated in the
CPA 100 mg/kg + L-BLP25 group in comparison to the
L-BLP25 alone group (Figures 4A and 4B). This could be
due to elevated levels of IFN-γ seen in the CPA 100 mg/kg +
L-BLP25 group. Inflammatory chemokines like IP-10 and
MIG are known chemoattractants for T-lymphocytes [28].
To determine the effect of low versus high, cytotoxic-
dose CPA on serum Th1/Th2 cytokine polarization as well
as on inflammatory cytokines, we analyzed serum samples
IL-1α

























































































































Figure 2 Pro-inflammatory cytokines at different stages of tumor progression. Serial serum specimens were collected via submandibular
bleeds following urethane doses 5, 8, and 10 and then every four weeks thereafter until study termination. Blood was pooled (n = 6), and the
serum was isolated and analyzed for the presence of 20 cytokines. Concentrations represent the mean of pooled samples and bars represent the
range. Arrows indicate the points at which L-BLP25 cycles one and two were begun in the L-BLP25 cycle-dependent studies.
Wurz et al. Journal of Translational Medicine 2013, 11:64 Page 7 of 13
http://www.translational-medicine.com/content/11/1/64collected 24 h following administration of the 100 mg/kg
and 300 mg/kg doses of CPA. No evidence supporting a
Th2 to Th1 shift in cytokine response following low-dose
or high-dose CPA administration was observed (Figures 3E
and 3F). For inflammatory cytokines, the levels of KC and
MIG were elevated in the 100 mg/kg group compared to
the 300 mg/kg group (Figure 4C).
Cycle-dependent effects of L-BLP25 on tumor incidence
No significant differences in the number of tumor foci
were observed following eight weekly treatments with L-BLP25, either alone or with CPA pretreatment (Figure 5).
In the two-cycle dosing study, however, a significant re-
duction in the number of tumor foci was observed in the
L-BLP25 + CPA 100 mg/kg treatment group compared
to the untreated group (p < 0.01). Interestingly, both the
L-BLP25 alone and CPA 100 mg/kg groups in the two-
cycle study showed a trend toward a reduced number of
tumor foci compared to the untreated group, although
statistical significance was not achieved (Figure 5). This
result suggests that adding a second cycle of CPA and/or
L-BLP25 administration may be important with respect to
Post L-BLP25 Dose 4

































































































































































































































































Figure 3 Effects of CPA alone and in combination with L-BLP25 on serum Th1/Th2 cytokines. Serial whole blood specimens were
collected via submandibular bleeds 24 hours after the 4th (A, B) and 8th (C, D) doses of L-BLP25, and 24 hours following the 100- or 300-mg/kg
CPA administrations (E, F). Blood was pooled within each treatment group (n = 3-6 depending on blood volume obtained), and the serum was
isolated and analyzed for the presence of 20 cytokines. Serum concentrations represent the mean and bars represent the range. The serum
concentrations of IFN-γ were noticeably higher in the mice treated with CPA + L-BLP25 compared to those treated with L-BLP25 alone.
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Figure 4 Effects of CPA alone and in combination with L-BLP25 on serum pro-inflammatory cytokines. Serial serum specimens were
analyzed for 20 cytokines 24 hours after the 4th (A) and 8th (B) doses of L-BLP25, and 24 hours after the CPA 100- and 300-mg/kg doses
(C). Blood was pooled within each treatment group (n = 3-6, depending on blood volume obtained). For each treatment group, serum
concentrations represent the mean and bars represent the range. Serum concentrations of IP-10, MIG, MIP-1α and MCP-1 were elevated in the
CPA + L-BLP25 group compared to vaccine alone.














































































Figure 5 Cycle-dependent antitumor activity of L-BLP25. In the
single-cycle study (A), male MUC1.Tg mice were given one cycle of
eight weekly doses of L-BLP25 starting immediately following
urethane induction and then followed for 20 additional weeks. In
the two-cycle study (B), MUC1.Tg mice were given an additional
cycle of L-BLP25 starting 11 weeks after the end of the first cycle
and continuing weekly until the conclusion of the study in Week 41.
The only statistically significant difference in number of tumor foci
(p < 0.01) was observed between the untreated and CPA + L-BLP25
groups following two cycles of L-BLP25 (B). In both studies, CPA
was administered three days prior to the start of each cycle of
L-BLP25. Data are shown as average number of tumor foci +
standard deviation.
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levels of inflammatory cytokines were flat in Week 14
when L-BLP25 treatment was begun in the single-cycle
study; however, when the second cycle of L-BLP25 treat-
ment was begun in Week 32 in the two-cycle study, serum











































Figure 6 IFN-γ immune response and Th1, Th2, and average inflamm
study. Luminex (A) and ELISpot (B) analyses were performed on four mice
Serum samples from individual mice were analyzed for the presence of 25
bars represent positive standard deviation.which may be associated with lung tumor development.
This observation may explain in part the antitumor activ-
ity of L-BLP25 treatment in the two-cycle study.
Figure 6 shows the serum concentrations of Th1, Th2,
and inflammatory cytokines (Figure 6A), as well as the
corresponding IFN-γ immune response in the 16 mice
used in the ELISpot analysis for the two-cycle study
(Figure 6B). Although L-BLP25 alone and with CPA pre-
treatment produced a specific IFN-γ immune response,
only L-BLP25 with CPA pretreatment showed detectable
serum levels of IFN-γ (Figure 6A). Taken together with
the tumor foci data, these results suggests that L-BLP25
with CPA pretreatment is more effective than L-BLP25
alone, and that the effects of L-BLP25 on lung tumor
control require at least two cycles of treatment. Ongoing
studies are designed to correlate inflammatory serum cy-
tokines and tumor foci to overall survival following mul-
tiple cycles of L-BLP25.
Discussion
It is well known that the biologic effects of low-dose CPA
differ from higher, cytotoxic doses. The immunomodulating
capacity of low-dose CPA has been shown to reduce both
the number of T-regulatory cells (T-regs) [29-33] and their
immunosuppressive functionality in mice [32] and humans
[30]. Based on these observations, CPA at a low dose of
300 mg/m2 is being used in all human L-BLP25 clinical
trials with the rationale of potentiating the immune re-
sponse to L-BLP25. Previous studies have shown that
low-dose CPA augments delayed-type hypersensitivity
(DTH) responses to antigen by selectively suppressing
CD4 + CD25+ T-reg cells while having relatively little
effect on CD8+ cytotoxic T-cells or the CD4+/CD8+
cell ratio [28-36]. T-regulatory cells are known to suppress
the immune response against tumors [29,37,38]. Higher,
cytotoxic doses of CPA impact all of the T-lymphocyte













































atory serum cytokine concentrations in the L-BLP25 two-cycle
from each treatment group at the conclusion of the study (Week 41).
cytokines. For all analyses, n = 4. SFC = spot forming colonies. Error
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[29,33]. Thus, a cytotoxic dose of CPA can impair the im-
mune response to tumor-associated antigens [29]. These
observations are consistent with Motoyoshi et al. who
showed that low-dose CPA produced an antitumor im-
mune response by selectively depleting Tregs in immuno-
competent mice, while the effects of high-dose CPA were
attributable solely to its cytotoxic effects [33]. In the
present study, we showed that pretreatment with low-dose
CPA (100 mg/kg) potentiated the L-BLP25-induced Th1
cytokine response, as demonstrated by elevated IFN-γ and
IL-2 levels. These results are in accordance with
previous findings by Machiels et al. who demonstrated
that CPA, when given in a defined sequence with a
GM-CSF-secreting, neu-expressing whole-cell vaccine,
enhanced the efficacy of the vaccine and appeared to
amplify the Th1 neu-specific T-cell response [39]. The
combination of CPA and L-BLP25 has already been
employed in clinical trials in non-small cell lung cancer.
The malignant potential and progression of the urethane-
induced tumors characterized in this study cannot be easily
predicted. In many cases, urethane-induced lung tumors
in mouse models are adenomas and do not progress to
adenocarcinomas with metastasis. However, this model
may be advantageous for preclinical testing, given that
cancer vaccines seem to be more effective in patients with
low tumor burden or indolent disease [40]. Although lung
cancer is notoriously difficult to treat, even in its early
stages, the fact that a modest yet significant reduction in
the number of tumor foci following two cycles of L-BLP25
treatment was encouraging. In view of this observation,
our model may prove more clinically relevant in deter-
mining the most effective combinations of L-BLP25 and
chemotherapeutic agents or other immunotherapies. For
example, the timing of L-BLP25/CPA combination ther-
apy may be critical with respect to antitumor activity. The
kinetics of serum pro-inflammatory cytokines may be
associated with tumor development and progression,
which in turn may be useful in tailoring the timing of
immunotherapy/chemotherapy treatment regimens. In
the two-cycle L-BLP25 study, reductions in the num-
bers of tumor foci were associated with treatments dur-
ing a period when serum pro-inflammatory cytokines
were increasing.
Conclusions
Although it was recently announced that the phase III
trial of L-BLP25 in patients with unresectable, locally ad-
vanced stage IIIA or IIIB non-small cell lung cancer did
not meet its primary endpoint of increasing overall sur-
vival, important scientific insights to the potential for
immunotherapies were noted. In the present preclinical
study, we showed a rather modest antitumor response,
which is consistent with the primary endpoint result ofthe phase III trial. However, only the publication of the
detailed results of the phase III trial will allow further
comparisons and conclusions between patients or sub-
groups of patients and this preclinical model. Translating
preclinical research also presents theoretical problems, as
we recently summarized [41]. The lung cancer model de-
scribed here offers a platform for developing effective
immunotherapy combinations, as well as combinations
of immunotherapy with targeted therapy. Future studies
examining inflammatory cytokines as biomarkers and
surrogate measures of tumor development and tailoring
immunotherapy treatment to a cytokine response are
warranted.
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